Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Comparative Trial Between Bexxar and Zevalin

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				CCBX001-053 NCT00078676


2.		Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				60 and over				Pharmaceutical / Industry				307940/106-20 NCT00322218


3.		A Study of Two Associations of Rituximab and Chemotherapy, With a PET–Driven Strategy, in Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 59				Other				2007.462 NCT00498043


4.		Safety Study to Evaluate Induction and Consolidation Treatment Combination in Mantle Cell Lymphoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 70				Other				GELTAMO-LCM-04-02 NCT00505232


5.		A Study of Zevalin and Simultaneous Application of BEAM High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 65				Other				DSHNHL 2004-R4 DSHNHL 2004-R4, NCT00521560


6.		Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-Based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 65				Other				CHUBX 2007/11 NCT00607854


7.		Allogenic Stem Cell Transplantation (SCT) With Non-Myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 65				Other				GELTAMO-Z-RIC-Allo EuDRACT nº:2007-003302-10, NCT00644371


8.		ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				18 to 75				Other				ZAR2007 NCT00662948

Last Modified: 11/16/2006 First Published: 10/21/2006


9.		Phase I Study of a Conditioning Regimen Comprising High-Dose Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Vinorelbine Ditartrate- and Filgrastim (G-CSF)-Mobilized Autologous Stem Cell Transplantation in Elderly Patients With Relapsed or Refractory CD20-Positive Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				65 and over				Other, Pharmaceutical / Industry				SWS-SAKK-37/05 EU-20648, SPRI-SWS-SAKK-37/05, NCT00392691

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute